Hims & Hers Health ($HIMS) stock recently earned a new Buy rating from Barclays at a price target of $48. Barclays sees potential for over 20% ...

Hims & Hers wants to launch its own weight loss program with GLP-1s like Ozempic. CEO Andrew Dudum worries about three challenges to the new market.

If you have been wondering whether Hims & Hers Health is still a smart buy after its huge run, you are not alone. This stock has quickly moved from niche telehealth play to mainstream market talking ...

Hims & Hers leads three healthcare IT stocks up over 20% in 2025, as digital care, remote monitoring and data platforms gain traction.

Hims & Hers compounded GLP-1 — the same ingredient as Ozempic — will be priced at $200 a month. Investors are loving the announcement.

Hims & Hers Health (NYSE: HIMS), a telehealth platform, has recently announced its Q1 financial results, showing notable year-over-year growth. The company reported adjusted earnings per share of ...

Hims & Hers has drawn scrutiny for selling compounded GLP-1 treatments – lower-cost, unapproved alternatives to blockbuster ...

We're coming to the close of 2025, and it has been an excellent year for stocks. The S&P 500 is up by a healthy 14%, while the tech-dominated Nasdaq Composite has jumped 18%, propelled by the growth ...

According to Benzinga Pro, Hims & Hers Health Inc's peer group average for short interest as a percentage of float is 7.95%, which means the company has more short interest than most of its peers. Did ...

Hims & Hers Health Inc (NYSE:HIMS) shares have surged 17.4% to $49.66 this week following a strong first-quarter earnings report released late Monday. What To Know: The telehealth company reported ...

Hims reports that a recent survey shows 64% of Americans feel healthier in 2025, focusing on mental health, sleep, and ...

In recent years, we've seen a broader dialogue around the benefits of creating affordable, accessible health care for all—and whether or not it's actually achievable. While there's still plenty of ...